Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework.
An allocation of $2,670 distributed equally across three carefully vetted ultra-high-yield securities, each offering yields exceeding 6%, can reasonably generate approximately $300 in annual dividend income.
The challenge lies not in identifying high-yield opportunities, but in distinguishing between genuinely durable dividend streams and those backed by unsustainable payout structures.
Motley Fool’s recent analysis identifies three securities that balance yield potential with fundamental strength.
The math is compelling: a $890 position in each of AGNC Investment, Pfizer, and PennantPark Floating Rate Capital yields an average of 11.25%, translating to your $300 target.
What separates these three from the dividend garbage heap is durability.
Each operates a repeatable business model that generates cash reliably, whether through mortgages, pharmaceuticals, or secured business loans.
3 stocks to consider for $300 of dividend income
1. AGNC Investment (AGNC)
AGNC Investment is what happens when you strip Wall Street down to its essential function: borrowing cheap, lending expensive.
This mortgage REIT borrows at short-term rates and buys agency mortgage-backed securities yielding higher long-term returns.
The federal government backs these mortgages, which is why AGNC’s 13.3% yield feels less reckless than it sounds.
A $890 position yields roughly $118 annually. The real kicker? AGNC has paid its shareholders $0.12 monthly for over five years straight, a remarkable feat given the interest-rate gyrations the markets have endured.
2. Pfizer (PFE)
Pfizer’s wound has been self-inflicted. The company rode the COVID windfall to $56 billion in combined vaccine and oral drug sales in 2022, then watched those therapies normalize.
Investors panicked. The stock price plummeted. Yield jumped to 6.9%.
Here’s the reality: Pfizer has already turned the corner.
Guidance for 2025 targets $62 billion in sales, 48% revenue growth over five years, with the company expanding well beyond pandemic payoffs.
A $890 stake generates roughly $61 in annual income. More importantly, Pfizer has raised its dividend for 16 consecutive years, a track record that matters in uncertain times.
3. PennantPark floating rate capital (PFLT)
PennantPark is a business development company, essentially, a lender to mid-market firms shut out of traditional banking.
Its $2.77 billion portfolio is 90% first-lien secured debt, meaning creditors like PennantPark are first in line if a borrower defaults. That structure explains how the company sustains a 13.6% yield.
A $890 investment delivers roughly $121 annually. What’s attractive here is rate sensitivity: 99% of PFLT’s loan portfolio carries variable rates.
If the Fed cuts gradually (as expected), competitors’ yields shrink while PFLT’s remains stable longer—a genuine advantage.
Risk-adjusted income strategy for 2026
Three equal $890 positions targeting $300 in income are achievable with AGNC, Pfizer, and PennantPark. But each carries sector-specific risks. AGNC depends on the Fed pivot.
Pfizer faces drug-pricing headwinds. PFLT’s economics shift if rates fall sharply.
Before deploying capital, review each company’s latest earnings, check free cash flow trends, and stress-test your position sizes under different interest-rate scenarios.
High yield attracts for good reason. Dividend durability trumps chasing percentages.
The post 3 ultra-high-yield stocks to consider for $300 of dividend income in 2026 appeared first on Invezz
